Company Filing History:
Years Active: 2020-2024
Title: Herve Rhinn: Innovator in Gene Therapy
Introduction
Herve Rhinn is a prominent inventor based in New York, NY, known for his significant contributions to the field of gene therapy. With a total of 11 patents to his name, he has made remarkable strides in addressing neurodegenerative disorders through innovative therapeutic approaches.
Latest Patents
Among his latest patents is a groundbreaking application focused on gene therapy for neurodegenerative disorders. This application is a continuation of international patent application serial number PCT/US2018/054223, filed on October 3, 2018. It claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application Ser. No. 62/567,303, filed on October 3, 2017, entitled 'GENE THERAPIES FOR LYSOSOMAL DISORDERS', and 62/567,305, filed on October 3, 2017, entitled “GENE THERAPIES FOR LYSOSOMAL DISORDERS”. The entire contents of each of these applications are incorporated herein by reference. Another significant patent involves gene therapies for lysosomal disorders, which relates to compositions and methods for treating diseases associated with aberrant lysosomal function, such as fronto-temporal dementia (FTD). This disclosure provides expression constructs comprising a transgene encoding progranulin or a portion thereof, along with methods of treating FTD by administering such expression constructs to a subject in need thereof.
Career Highlights
Herve Rhinn has established himself as a key figure in the biotechnology sector, particularly through his work at Prevail Therapeutics, Inc. His innovative research and development efforts have positioned him at the forefront of advancements in gene therapy.
Collaborations
Herve collaborates with notable colleagues, including Asa Abeliovich and Laura Heckman, who contribute to the dynamic research environment at Prevail Therapeutics, Inc.
Conclusion
Herve Rhinn's contributions to gene therapy exemplify the impact of innovation in addressing complex medical challenges. His work continues to inspire advancements in the treatment of neurodegenerative disorders.